Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 3/20 | 0.63 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.63 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.63 |
| ▸ | ADCY5 | O95622 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.57 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906617 | 0.95 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL38913 | 0.94 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL5033136 | 0.90 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL14037129 | 0.89 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11222112 | 0.88 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL1532103 | 0.87 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL2638945 | 0.87 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL26981114 | 0.87 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL1074972 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL19631092 | 0.85 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1790 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995015983-A1 | PROCESS FOR IMMOBILISING BIOMOLECULES AND AFFINITY LIGANDS ON POLYMER CARRIERS | GLUESENKAMP KARL HEINZ (DE) | 1995-06-15 | — | — | WO | claimed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| CN-122038302-A | Modified T cells and methods of making and using the same | 哈佛学院校长同事会 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026102123-A1 | SEQUENCE CAPTURE TECHNOLOGY AND PROBE DESIGN | MONSANTO TECHNOLOGY LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE ARV TECH INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260132405-A1 | Modulation of Apolipoprotein C-III (ApoCIII) Expression in Lipoprotein Lipase Deficient (LPLD) Populations | IONIS PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-1560840-A2 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | Isis Pharmaceuticals, Inc. (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050164209-A1 | Hepatocyte free uptake assays | ISIS PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20050080246-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. | 2005-04-14 | — | — | US | disclosed |
| WO-2005013901-A2 | OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050026160-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2004044136-A2 | COMPOSITIONS COMPRISING ALTERNATING 2’-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-6602692-B1 | Reacting a water insoluble matrix having amino groups such as membranes, resins, microtiter plates, with an activating cyclobutene such as 1,2-diethoxycyclobut-1-en-3,4-dione and then incubating with an amino-functional protein | GLUESENKAMP KARL-HEINZ (DE) | 2003-08-05 | — | — | US | disclosed |
| WO-2003008550-A2 | SYNTHESIS OF OLIGONUCLEOTIDES ON SOLID SUPPORTS INCLUDING NON-REACTIVE SOLID DILUENTS | ISIS PHARMACEUTICALS, INC. (US) | 2003-01-30 | — | — | WO | disclosed |
| EP-1137658-A1 | METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000034303-A1 | METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080246-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | ADORA2A 1066/4885ADORA1 2142/4885ADORA2B 1543/4885 |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | ADORA2A 276/4885ADORA1 181/4885ADORA2B 218/4885 |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | ADORA2A 828/4885ADORA1 1014/4885ADORA2B 2985/4885 |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, METTL16, NSUN2 | ADORA2A 2246/4885ADORA1 1287/4885ADORA2B 3423/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | ADORA2A 3858/4885ADORA1 3856/4885ADORA2B 4189/4885 |
| US-20050026160-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | NSUN2, RNMT, NSUN3 | ADORA2A 1066/4885ADORA1 2142/4885ADORA2B 1543/4885 |
| US-20260132405-A1 | Modulation of Apolipoprotein C-III (ApoCIII) Expression in Lipoprotein Lipase Deficient (LPLD) Populations | LPL, APOL1, PNLIP | ADORA2A 3152/4885ADORA1 2359/4885ADORA2B 1559/4885 |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | UPF1, NSUN2, CD4 | ADORA2A 2670/4885ADORA1 2796/4885ADORA2B 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.